Annual Accounts Receivable
$716.76 M
+$10.97 M+1.55%
December 31, 2024
Summary
- As of March 12, 2025, JAZZ annual accounts receivable is $716.76 million, with the most recent change of +$10.97 million (+1.55%) on December 31, 2024.
- During the last 3 years, JAZZ annual accounts receivable has risen by +$153.41 million (+27.23%).
- JAZZ annual accounts receivable is now at all-time high.
Performance
JAZZ Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$716.76 M
-$6.87 M-0.95%
December 31, 2024
Summary
- As of March 12, 2025, JAZZ quarterly accounts receivable is $716.76 million, with the most recent change of -$6.87 million (-0.95%) on December 31, 2024.
- Over the past year, JAZZ quarterly accounts receivable has stayed the same.
- JAZZ quarterly accounts receivable is now -0.95% below its all-time high of $723.64 million, reached on September 30, 2024.
Performance
JAZZ Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
JAZZ Accounts Receivable Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +1.6% | 0.0% |
3 y3 years | +27.2% | +14.2% |
5 y5 years | +101.3% | +14.2% |
JAZZ Accounts Receivable Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | at high | +27.2% | -0.9% | +27.2% |
5 y | 5-year | at high | +101.3% | -0.9% | +125.9% |
alltime | all time | at high | >+9999.0% | -0.9% | >+9999.0% |
Jazz Pharmaceuticals Accounts Receivable History
Date | Annual | Quarterly |
---|---|---|
Dec 2024 | $716.76 M(+1.6%) | $716.76 M(-0.9%) |
Sep 2024 | - | $723.64 M(+3.7%) |
Jun 2024 | - | $698.04 M(-1.3%) |
Mar 2024 | - | $707.10 M(+0.2%) |
Dec 2023 | $705.79 M(+8.3%) | $705.79 M(+12.4%) |
Sep 2023 | - | $627.84 M(+2.9%) |
Jun 2023 | - | $610.39 M(-2.2%) |
Mar 2023 | - | $623.94 M(-4.2%) |
Dec 2022 | $651.49 M(+15.6%) | $651.49 M(+8.4%) |
Sep 2022 | - | $601.18 M(+1.2%) |
Jun 2022 | - | $594.03 M(+3.8%) |
Mar 2022 | - | $572.39 M(+1.6%) |
Dec 2021 | $563.36 M(+42.1%) | $563.36 M(+12.9%) |
Sep 2021 | - | $499.02 M(-1.5%) |
Jun 2021 | - | $506.66 M(+22.4%) |
Mar 2021 | - | $413.98 M(+4.4%) |
Dec 2020 | $396.49 M(+11.4%) | $396.49 M(+9.6%) |
Sep 2020 | - | $361.66 M(+2.8%) |
Jun 2020 | - | $351.92 M(+10.9%) |
Mar 2020 | - | $317.30 M(-10.9%) |
Dec 2019 | $355.99 M(+34.9%) | $355.99 M(+33.3%) |
Sep 2019 | - | $267.03 M(-14.2%) |
Jun 2019 | - | $311.25 M(-2.9%) |
Mar 2019 | - | $320.49 M(+21.5%) |
Dec 2018 | $263.84 M(+17.7%) | $263.84 M(-5.6%) |
Sep 2018 | - | $279.44 M(+0.4%) |
Jun 2018 | - | $278.44 M(-1.1%) |
Mar 2018 | - | $281.42 M(+25.6%) |
Dec 2017 | $224.13 M(-4.3%) | $224.13 M(-13.3%) |
Sep 2017 | - | $258.62 M(+8.3%) |
Jun 2017 | - | $238.75 M(-1.8%) |
Mar 2017 | - | $243.03 M(+3.8%) |
Dec 2016 | $234.24 M(+11.7%) | $234.24 M(-1.6%) |
Sep 2016 | - | $238.07 M(+2.7%) |
Jun 2016 | - | $231.84 M(+3.6%) |
Mar 2016 | - | $223.80 M(+6.7%) |
Date | Annual | Quarterly |
---|---|---|
Dec 2015 | $209.69 M(+12.5%) | $209.69 M(+7.1%) |
Sep 2015 | - | $195.82 M(+1.1%) |
Jun 2015 | - | $193.65 M(+2.1%) |
Mar 2015 | - | $189.68 M(+1.8%) |
Dec 2014 | $186.37 M(+49.3%) | $186.37 M(-0.7%) |
Sep 2014 | - | $187.60 M(+16.7%) |
Jun 2014 | - | $160.78 M(+3.7%) |
Mar 2014 | - | $154.99 M(+24.2%) |
Dec 2013 | $124.81 M(+65.3%) | $124.81 M(+10.2%) |
Sep 2013 | - | $113.27 M(-0.7%) |
Jun 2013 | - | $114.08 M(+21.6%) |
Mar 2013 | - | $93.83 M(+24.3%) |
Dec 2012 | $75.48 M(+119.6%) | $75.48 M(-14.5%) |
Sep 2012 | - | $88.30 M(+13.0%) |
Jun 2012 | - | $78.13 M(+39.2%) |
Mar 2012 | - | $56.14 M(+63.3%) |
Dec 2011 | $34.37 M(+55.7%) | $34.37 M(+9.4%) |
Sep 2011 | - | $31.43 M(+25.7%) |
Jun 2011 | - | $25.00 M(+16.9%) |
Mar 2011 | - | $21.38 M(-3.2%) |
Dec 2010 | $22.08 M(+79.3%) | $22.08 M(+56.7%) |
Jun 2010 | - | $14.10 M(+17.9%) |
Mar 2010 | - | $11.96 M(-2.9%) |
Dec 2009 | $12.31 M(+85.4%) | $12.31 M(+33.8%) |
Sep 2009 | - | $9.20 M(+0.1%) |
Jun 2009 | - | $9.20 M(+31.2%) |
Mar 2009 | - | $7.01 M(+5.6%) |
Dec 2008 | $6.64 M(+23.3%) | $6.64 M(-0.6%) |
Sep 2008 | - | $6.69 M(+28.1%) |
Jun 2008 | - | $5.22 M(-1.7%) |
Mar 2008 | - | $5.31 M(-1.5%) |
Dec 2007 | $5.39 M(+0.2%) | $5.39 M(-17.9%) |
Sep 2007 | - | $6.57 M(+1.6%) |
Jun 2007 | - | $6.46 M(+4.8%) |
Mar 2007 | - | $6.17 M(+14.6%) |
Dec 2006 | $5.38 M(+49.6%) | $5.38 M(+49.6%) |
Dec 2005 | $3.60 M | $3.60 M |
FAQ
- What is Jazz Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals annual accounts receivable year-on-year change?
- What is Jazz Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Jazz Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of JAZZ is $716.76 M
What is the all time high annual accounts receivable for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual accounts receivable is $716.76 M
What is Jazz Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, JAZZ annual accounts receivable has changed by +$10.97 M (+1.55%)
What is Jazz Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of JAZZ is $716.76 M
What is the all time high quarterly accounts receivable for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly accounts receivable is $723.64 M
What is Jazz Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, JAZZ quarterly accounts receivable has changed by $0.00 (0.00%)